期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤表观遗传学 被引量：7

Epigenetics of tumor
暂未订购
导出
摘要 表观遗传学(epigenetics)是指不涉及核苷酸序列的改变、但以通过有丝分裂和减数分裂进行遗传的生物现象为内容的生命学科。表观遗传修饰异常广泛存在于肿瘤的发生、发展过程中,所以近年来备受研究者们的关注。 Epigenetics studies biological phenomenon that inheritance occurs through mitosis and meiosis without nucleotide sequence changes. Epigenetic modification abnormalities exist extensively in the process of carcinogenesis and tumor development, and have drawn attention of researchers in recent years.
作者 金铁峰 张美花 林贞花
机构地区 延边大学基础医学院病理学教研室
出处 《基础医学与临床》 CSCD 北大核心 2011年第2期204-206,共3页 Basic and Clinical Medicine
基金 国家自然科学基金(30960120)
关键词 表观遗传学 DNA甲基化 组蛋白修饰 染色质重塑 非编码RNA调控 epigenetics DNA methylation histone modification chromatin remodeling non-coding RNA regulation
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1王娟,陈秀华.表观遗传学的研究进展及其在抗肿瘤领域的应用[J].世界临床药物,2008,29(11):683-687. 被引量：5
  • 2Bird A. Perceptions of epigenetics [ J ]. Nature, 2007, 447 : 396 - 398.
  • 3凡时财,张学工.DNA甲基化的生物信息学研究进展[J].生物化学与生物物理进展,2009,36(2):143-150. 被引量：35
  • 4郑丹,刘彬彬,刘银坤.肿瘤表观遗传学研究进展[J].世界华人消化杂志,2007,15(24):2631-2637. 被引量：8
  • 5余宗涛,高琼,吕军,张吉才,袁亚莉.肺癌患者PTEN基因启动子高甲基化的检测[J].基础医学与临床,2008,28(8):855-858. 被引量：4
  • 6Lattal KM, Barrett RM, Wood MA. Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction [ J ]. Behav Neurosci, 2007, 121 : 1125 - 1131.
  • 7Mai A, Perrone A, Nebbioso A, et al. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities[ J]. Bioorg Med Chem Lett, 2008, 18:2530-2535.
  • 8Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling [ J ].Trends Mol Med, 2007, 13:373-380.
  • 9吕锋,邵泽勇,谢朝良.表观遗传学在肿瘤诊治中的应用[J].西部医学,2008,20(1):196-199. 被引量：1
  • 10Link PA, Baer MR, James SR, et al. P53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia [ J ]. Cancer Res, 2008, 68 : 9358 - 9366.

二级参考文献84

  • 1Liang-Liang Yu,Hong-Gang Yu,Jie-Ping Yu,He-Sheng Luo,Xi-Ming Xu,Jun-Hua Li.Nuclear factor-kB p65(RelA)transcription factor is constitutively activated in human colorectal carcinoma tissue[J].World Journal of Gastroenterology,2004,10(22):3255-3260. 被引量：15
  • 2李晓晖,李建勋,李世荣,修志龙,西野宪和.环肽类组蛋白去乙酰化酶抑制剂[J].化学进展,2007,19(5):762-768. 被引量：7
  • 3Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 [J]. Gene Ther, 2006, 13(3) : 225 -234.
  • 4Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs [J]. Pharmacol Ther, 2008, 117(1): 94 -104.
  • 5Luo Qing, Kang Quan, Song Wenxin, et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing [ J]. Gene, 2007, 395 (1 - 2) : 160 - 169.
  • 6Lin X, Ruan X, Anderson MG, et al. siRNA-mediated offtarget gene silencing triggered by a 7 nt complementation [J]. Nucleic Acids Res, 2005, 33(14): 4527-4535.
  • 7Halder J, Kamat AA, Landen CN, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy [ J]. Clin Cancer Res, 2006, 12(16) : 4916 -4924.
  • 8Giladi H, Ketzinel Gilad M, Rivkin L, et al. Small interfeting RNA inhibits hepatitis B virus replication in mice [J]. Mol Ther, 2003, 8(5): 769-776.
  • 9Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis [J ]. Nat Med, 2003, 9(3): 347-351.
  • 10Li Guangming, Xie Qing, Shi Yi, et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats [J], J Gene Me, 2006, 8(7) : 889 -900.

共引文献49

同被引文献48

  • 1闫春燕,郑连斌,胡莹,张兴华,王志博,龚忱,武亚文.四川资阳汉族7项不对称行为特征的研究[J].山西大学学报（自然科学版）,2011,34(3):507-512. 被引量：11
  • 2曲国蕃,孙志海,李佳慧.与骨肉瘤预后相关的基因研究进展[J].基础医学与临床,2006,26(10):1157-1160. 被引量：1
  • 3于会新,郑连斌,陆舜华,刘海萍.佤族的6项不对称行为特征的研究[J].沈阳师范大学学报（自然科学版）,2007,25(1):87-91. 被引量：14
  • 4Frikeche J, Peric Z, Brissot E, et al. Impact of HDAC in- hibitors on dendritic cell functions [ J ]. Exp Hematol, 2012, 40:783 -791.
  • 5Mai A, Perrone A, Nebbioso A, et al. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities [ J ]. Bioorg Med Chem Lett, 2008, 18 : 2530 - 2535.
  • 6Lin Z, Bazzaro M, Wang MC, et al. Combination of pro- teasome and HDACs inhibitors for therapy of uterine cervi- cal cancer[ J]. Clin Cancer Res, 2009, 15:570 - 577.
  • 7Lee YS, Lim KH, Guo X, et al. The cytoplasmic deacety- lase HDAC6 is required for efficient oncogenic tumorigene- sis[ J]. Clin Cancer Res, 2008, 68:7561 -7569.
  • 8Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expres- sion is correlated with better survival in breast cancer[ J ].Clin Cancer Res, 2004, 10 : 6962 - 6968.
  • 9Meng J, Zhang HH, Zhou CX, et al. The histone deacety- lase inhibitor trichostatin A induces cell cycle arrest and ap- optosis in colorectal cancer cells via p53-dependent and -in- dependent pathways [ J ]. Oncol Rep, 2012, 28:384 - 388.
  • 10Buurman R, Giirlevik E, Schaffer V, et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells [ J ]. Gastroenterology, 2012, 143 : 811 - 820.

引证文献7

二级引证文献10

基础医学与临床
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部